# UNITy-BasED MR-Linac Adaptive Simultaneous Integrated Hypofractionated Boost Trial for High Grade Glioma in the Elderly

> **NCT05565521** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Sunnybrook Health Sciences Centre** · enrollment: 55 (estimated)

## Conditions studied

- Glioblastoma Multiforme, Adult
- Glioblastoma, IDH-mutant

## Interventions

- **RADIATION:** Dose escalation + Reduced Margin Adaptive Radiotherapy

## Key facts

- **NCT ID:** NCT05565521
- **Lead sponsor:** Sunnybrook Health Sciences Centre
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-12-13
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 55 (ESTIMATED)
- **Last updated:** 2026-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05565521

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05565521, "UNITy-BasED MR-Linac Adaptive Simultaneous Integrated Hypofractionated Boost Trial for High Grade Glioma in the Elderly". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05565521. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*